dalteparin has been researched along with tgx 221 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Angus, JA; Jones, C; Sturgeon, SA; Wright, CE | 1 |
1 other study(ies) available for dalteparin and tgx 221
Article | Year |
---|---|
Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat.
Topics: Animals; Anticoagulants; Bleeding Time; Blood Pressure; Cardiovascular Agents; Enoxaparin; Enzyme Inhibitors; Fibrinolytic Agents; Heart Rate; Male; Mesenteric Arteries; Morpholines; Muscle Relaxation; Muscle, Smooth, Vascular; Phosphoinositide-3 Kinase Inhibitors; Platelet Activation; Platelet Aggregation Inhibitors; Pyrimidinones; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Stress, Physiological; Substrate Specificity; Vascular Resistance | 2008 |